(firstQuint)Study to Evaluate Efficacy, Safety, and Tolerability of MT7117 in Subjects With Erythropoietic Protoporphyria.

 This is a Phase II, randomized, double-blind, placebo controlled study to assess the efficacy, tolerability, and safety of MT-7117 in subjects with EPP.

 The study consists of a 2 week screening period, a 16 week double-blind treatment period, and a 6 week follow-up period at Week 22.

 The total participation period is approximately 24 weeks.

.

 Study to Evaluate Efficacy, Safety, and Tolerability of MT7117 in Subjects With Erythropoietic Protoporphyria@highlight

The purpose of this study is to investigate the efficacy and safety of MT-7117 on sunlight exposure duration and tolerance in subjects with EPP.

